At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Spectroscopic MRI-Guided, Dose-Escalated Radiation Therapy for Newly-Diagnosed Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Dose-Escalated Radiation Therapy, Spectroscopic Magnetic Resonance Imaging, and 1 other intervention for Glioblastoma and Gliosarcoma. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma. Spectroscopic MRI can show doctors where the extent of tumor is in the brain beyond current clinical MRI scans by mapping areas of high tumor metabolism. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Spectroscopic MRI-guided radiation therapy may work better in treating patients with glioblastoma or gliosarcoma.
Study Details
Timeline
Interventions
Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
Patients will undergo sMRI scans within a 14 day window prior to starting treatment
Given PO